Immunogenic Cell Death Role in Urothelial Cancer Therapy
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2022-09-18 / Curr Oncol 2022 Sep;29(9):6700-6713Immune escape mechanisms and immunotherapy of urothelial bladder cancer
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2021-07-30 / J Clin Transl Res 2021 Aug;7(4):485-500Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
/in Dendritic Cells, International Publications, Prostate Cancer, Urothelial Carcinoma /von 2021-06-09 / Vaccines (Basel) 2021 Jun;9(6)Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
/in International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2021-05-27 / BMC Cancer 2021 May;21(1):625Cell Therapies in Bladder Cancer Management
/in Dendritic Cells, International Publications, Urothelial Carcinoma /von 2021-03-10 / Int J Mol Sci 2021 Mar;22(6)Novel immunotherapy combinations for genitourinary cancers
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
/in Dendritic Cells, Urothelial Carcinoma /von 2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2018-05-30 / Ther Apher Dial 2018 Jun;22(3):266-277Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2017-10-19 / Eur Urol Focus 2018 04;4(3):442-454
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de